Molecular Profiling for Individualized Treatment Plan for DIPG

NACompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

September 16, 2014

Primary Completion Date

December 19, 2018

Study Completion Date

February 24, 2019

Conditions
Diffuse Intrinsic Pontine Glioma (DIPG)
Interventions
OTHER

Specialized tumor board recommendation

A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.

RADIATION

Standard radiation therapy

Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.

Trial Locations (5)

20010

Children's National Medical Center, Washington D.C.

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

84113

University of Utah, Salt Lake City

92123

Rady Children's Hospital, San Diego

94158

University of California, San Francisco, San Francisco

All Listed Sponsors
collaborator

Translational Genomics Research Institute

OTHER

lead

University of California, San Francisco

OTHER

NCT02274987 - Molecular Profiling for Individualized Treatment Plan for DIPG | Biotech Hunter | Biotech Hunter